拉帕替尼对人卵巢癌SKOV3裸鼠移植瘤的影响

【目的】探讨新型靶向治疗药物拉帕替尼对人卵巢癌SKOV3裸鼠移植瘤生长的影响。【方法】将人SKVO3细胞株接种于裸小鼠胸壁皮下建立卵巢癌裸小鼠移植瘤模型。随机将其分为空白对照组（A组）和实验组（B组），实验组根据拉帕替尼药物浓度的不同分为两个亚组：100 mg/kg （B1）和200 mg/kg （B2），检测各组拉帕替尼用药前后荷瘤体积及裸鼠体质量的变化。【结果】拉帕替尼可显著抑制SKOV3裸小鼠移植瘤的生长，呈剂量依赖性，B2组抑瘤率显著高于B1组，其差异有统计学意义（P＜0．05），但小鼠体质量用药前后比较无显著性差异（P＞0．05）。【结论】拉帕替尼可显著缩小人卵巢癌细胞株SKVO3裸鼠移植瘤的体积，为卵巢癌新型靶向治疗提供了理论基础。

Impact of Lapatinib on Transplanted Tumor in Nude Mouse from Human Ovarian Cancer Cell line SKOV3

Objective]To explore the impact of new targeted therapy drug lapatinib on transplanted tumor of nude mouse from human ovarian cancer cell line SKOV3 .Methods]Human ovarian cancer cell line SKOV3 was inoculated into subcutaneous tissue of nude mouse＇s chest wall in order to establish nude mouse model with transplanted tumor of ovarian cancer successfully .Then they were randomly divided into blank control group （group A） and experimental group （group B） ,experimental group were divided into two subgroups by different drug concentrations of lapatinib ：100mg/kg（B1 ） and 200 mg/kg（B2 ） ,the changes of the volume of bearing cancer and the weight of nude mouse before and after lapatinib treatment were examined .Results] Lapatinib can markedly inhibit the proliferation of transplanted tumor in nude mouse from SKOV 3 in a dose-dependent manner .The tumor inhibition rate of group B2 was markedly higher than that of group B1 ,and there was significant difference between two groups（ P〈0 .05） ,but there was no significant difference in mouse weight between before and after medication （ P 〉 0 .05） .Conclusion]Lapatinib can markedly reduce the volume of transplanted tumor in nude mouse from human ovarian cancer cell line SKOV 3 ,and provide the theoretical basis for its application in ovarian cancer .